Recent News

• 11.05.2026 - Celldex Reports Third Quarter Financial Results and Provides Corporate Update
• 11.04.2026 - Celldex to Present at Upcoming Investor Conferences
• 09.22.2026 - Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints
• 09.08.2026 - Celldex to Present at Upcoming Investor Conference
• 08.06.2026 - Celldex Reports Second Quarter Financial Results and Provides Corporate Update
• 07.21.2026 - Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis
• 07.15.2026 - Celldex Announces Planned Transition of Chief Financial Officer
• 06.14.2026 - Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting
• 06.14.2026 - Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
• 06.10.2026 - Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress

Recent Filings

• 10.07.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 09.22.2026 - 8-K Current report
• 09.22.2026 - EX-99.1 EX-99.1
• 08.14.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.14.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.06.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.06.2026 - 8-K Current report
• 08.06.2026 - EX-99.1 EX-99.1
• 07.15.2026 - 8-K Current report
• 06.29.2026 - 4 Statement of changes in beneficial ownership of securities